JP2005525371A - 糖尿病および他の疾患を治療するための二環式複素環 - Google Patents

糖尿病および他の疾患を治療するための二環式複素環 Download PDF

Info

Publication number
JP2005525371A
JP2005525371A JP2003574134A JP2003574134A JP2005525371A JP 2005525371 A JP2005525371 A JP 2005525371A JP 2003574134 A JP2003574134 A JP 2003574134A JP 2003574134 A JP2003574134 A JP 2003574134A JP 2005525371 A JP2005525371 A JP 2005525371A
Authority
JP
Japan
Prior art keywords
alkyl
compound
amino
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003574134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525371A5 (cg-RX-API-DMAC7.html
Inventor
マグナス ファール,
キャサリン タッジアン,
フセイン エー. アル−シャマ,
アンドリア ファンジュル ギアチーノ,
カリン ジャキュボウィック−ジェラルドン,
ジャンフ グオ,
リチャード エム. ファイン,
ライル ダブリュー. スプルース,
ジェイムス ダブリュー. ザッフ,
Original Assignee
インサイト サン ディエゴ インコーポレイテッド
オーソ−マクネイル ファーマシューティカル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インサイト サン ディエゴ インコーポレイテッド, オーソ−マクネイル ファーマシューティカル インコーポレイテッド filed Critical インサイト サン ディエゴ インコーポレイテッド
Publication of JP2005525371A publication Critical patent/JP2005525371A/ja
Publication of JP2005525371A5 publication Critical patent/JP2005525371A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003574134A 2002-03-08 2003-03-07 糖尿病および他の疾患を治療するための二環式複素環 Pending JP2005525371A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36273202P 2002-03-08 2002-03-08
PCT/US2003/007240 WO2003075858A2 (en) 2002-03-08 2003-03-07 Bicyclic heterocycles for the treatment of diabetes and other diseases

Publications (2)

Publication Number Publication Date
JP2005525371A true JP2005525371A (ja) 2005-08-25
JP2005525371A5 JP2005525371A5 (cg-RX-API-DMAC7.html) 2006-03-23

Family

ID=27805219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003574134A Pending JP2005525371A (ja) 2002-03-08 2003-03-07 糖尿病および他の疾患を治療するための二環式複素環

Country Status (9)

Country Link
US (1) US7196108B2 (cg-RX-API-DMAC7.html)
EP (1) EP1487446A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005525371A (cg-RX-API-DMAC7.html)
AU (1) AU2003223233A1 (cg-RX-API-DMAC7.html)
BR (1) BR0308278A (cg-RX-API-DMAC7.html)
CA (1) CA2478765A1 (cg-RX-API-DMAC7.html)
IL (1) IL163953A0 (cg-RX-API-DMAC7.html)
TW (1) TWI277415B (cg-RX-API-DMAC7.html)
WO (1) WO2003075858A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536693A (ja) * 2010-09-01 2013-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脂肪生成および筋線維芽細胞分化を制御する薬剤についての細胞培養スクリーニング
US10494402B2 (en) 2012-11-25 2019-12-03 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384825A (zh) * 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
BR0207846A (pt) * 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) * 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Rxr活性化分子
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
ATE540047T1 (de) * 2002-06-25 2012-01-15 Helicon Therapeutics Inc Gedächtnisveränderung durch beeinflussung der funktion von staufen
PT1572215E (pt) 2002-12-20 2009-12-09 Glaxo Group Ltd Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas
BRPI0409501A (pt) * 2003-04-18 2006-04-18 Incyte San Diego Inc compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP2008538576A (ja) * 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
CN101316821A (zh) * 2005-09-30 2008-12-03 詹森药业有限公司 作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的二氢-[1h]-喹啉-2-酮衍生物
WO2010135524A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
MX2011012584A (es) 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2012153775A1 (ja) 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (cg-RX-API-DMAC7.html) 2011-07-01 2018-04-28
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
DE3874257T2 (de) * 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
EP0595868B1 (en) * 1991-07-22 1998-11-25 Pfizer Inc. Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene
DE69333894D1 (de) 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
WO1994012880A2 (en) 1992-11-25 1994-06-09 La Jolla Cancer Research Foundation Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
ES2130597T3 (es) * 1994-02-17 1999-07-01 American Home Prod Derivados de bifenilo sustituido como inhibidores de la fosfodiesterasa.
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
US5520752A (en) * 1994-06-20 1996-05-28 The United States Of America As Represented By The Secretary Of The Army Composite solders
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
CA2223489A1 (en) 1995-07-17 1997-02-06 Joseph A. Fontana Method for treating cancer using ahpn
WO1997027191A1 (en) 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
US6127415A (en) * 1996-07-08 2000-10-03 Galderma Research & Development, S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
CA2300813A1 (en) 1997-08-21 1999-03-04 Hiroyuki Odaka Anti-inflammatory agent
EP1048659A4 (en) 1997-11-12 2002-11-20 Inst Med Molecular Design Inc Retinoid receptor Antagonist
US6235996B1 (en) * 1998-01-28 2001-05-22 International Business Machines Corporation Interconnection structure and process module assembly and rework
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU3111700A (en) 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
CN1384825A (zh) * 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
PT1142885E (pt) 1999-11-12 2007-02-28 Fujimoto Brothers Co Ltd Derivados de 2-(n-cianoimino)tiazolidin-4-ona
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
BR0207846A (pt) * 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Rxr活性化分子
AU2002258550B2 (en) 2001-03-14 2006-04-27 Eli Lilly And Company Retinoid X receptor modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−x受容体モジュレーターを含んで成る併用療法
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
BRPI0409501A (pt) * 2003-04-18 2006-04-18 Incyte San Diego Inc compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536693A (ja) * 2010-09-01 2013-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脂肪生成および筋線維芽細胞分化を制御する薬剤についての細胞培養スクリーニング
US10494402B2 (en) 2012-11-25 2019-12-03 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
US10766927B2 (en) 2012-11-25 2020-09-08 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

Also Published As

Publication number Publication date
TW200304814A (en) 2003-10-16
WO2003075858A2 (en) 2003-09-18
US7196108B2 (en) 2007-03-27
AU2003223233A2 (en) 2003-09-22
AU2003223233A1 (en) 2003-09-22
EP1487446A2 (en) 2004-12-22
TWI277415B (en) 2007-04-01
CA2478765A1 (en) 2003-09-18
WO2003075858A3 (en) 2004-03-18
US20040034004A1 (en) 2004-02-19
EP1487446A4 (en) 2006-04-19
BR0308278A (pt) 2005-02-09
IL163953A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
US20040034004A1 (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
KR101589332B1 (ko) 2h-크로멘 화합물 및 그의 유도체
CN101657443B (zh) 作为白三烯生物合成抑制剂的[1,2,3]三唑取代的喹啉和香豆素
JP3940430B2 (ja) C型肝炎ウイルスrna依存rnaポリメラーゼ阻害剤ならびにそれを用いた組成物および治療
US10954228B2 (en) 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
JP4815083B2 (ja) 複素環化合物およびそれの使用方法
DE69517821T2 (de) Bisarylcarbinol zimtsäure-derivate zur hemmung leukotriener biosynthese
NO322701B1 (no) Benzyliden-tiazolidindioner, anvendelse og fremstilling derav, samt farmasoytisk preparat.
WO2004080990A1 (ja) C-グリコシド誘導体又はその塩
JP2005530705A (ja) 糖尿病および他の疾患を治療するための複素環アミド誘導体
AU2006227524B2 (en) Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
US20050038098A1 (en) Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
HK1047591B (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20090708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091204